Frost & Sullivan Independent Equity Research

Oramed Pharmaceuticals Inc.: Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed’s clinical progress meets our expectations, stock target price remains at NIS 53.2.

Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc)

Company: Oramed Pharmaceuticals Inc.        

Sector: Pharmaceuticals

Report type: Update for the quarter ending 31 May 2018

Published on: 24 July, 2018

Oramed research articles: